Skip to content
MARKETS / NASDAQ / VSTM
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Verastem, Inc. VSTM

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$30.9M
▲ 209.1% YoY
$-209.5M
In brief

What this company does

We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States (“U.S.”), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (“LGSOC”) who have received prior systemic therapy. We are also conducting RAMP 301, a Phase 3 trial designed to evaluate avutometinib plus defactinib versus Investigator’s Choice of Treatment (“ICT”) in patients with recurrent LGSOC with and without a KRAS mutation. Our pipeline includes clinical-stage programs, preclinical research programs and externally partnered early-stage programs.

Written from the business description in Verastem, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.

Growth
USD 30.9M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 30.9 · Net income -209.5
40M80M-80M-160M20112013201520172019202120232025
Compound annual growth
+128.4%
−19.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −19.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−678 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -550.3% · Net -677.6%
-1000%-2000%-3000%20112013201520172019202120232025
ROE
FY2025 · ROE -1480.2%
-500%-1000%20112013201520172019202120232025

Each USD of equity lost 1480 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -104.8
-50M-100M20112013201520172019202120232025

Total assetsUSD 246.4M
EquityUSD 57.2M
CashUSD 205.0M
Current ratio3.09×

Equity funds 23% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.0·0.00.00.10.00.0·······
Operating income $B−0.2−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.2−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
Income tax $B·0.0·0.00.00.00.00.0·······
Net income $B−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
Free cash flow $B·−0.1··−0.1−0.0−0.1−0.1·−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−3.02−3.66−3.96−4.57−4.90−0.44−2.00−1.37−1.76−0.99−1.61−2.07−1.82−1.70−10.59
Dividend / sh $···············
Payout %···············
ROE %−1480.2−917.4−166.8−109.4−70.2−110.6−227.0−79.6−104.3−41.7−60.5−51.8−39.6−82.3·
Shares out B0.080.040.030.020.190.170.080.070.050.040.040.030.030.020.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 61 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 33 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inMassachusetts
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image